An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis

Category Primary study
Conference67th American Society of Hematology Annual Meeting, ASH 2025
Year 2025
This article has no abstract
Epistemonikos ID: 05363cff400b1da8314dd29de4eacebd7abc4aa4
First added on: Jun 15, 2026